Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yang Yin Fu Zheng Jie Du Therapy for Recurrent HCC
NCT04264962Phase 1Completed
- Sponsor
- Beijing Ditan Hospital
- Start
- Jan 2017
- Primary completion
- Feb 2021
- Modality
- HM (Herbal Medicine), Combination therapy
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Yangyin Fuzheng Jiedu Prescription in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Recurrance rate at 1 year. Started Jan 2017; status: completed.
02
Drugs
Yangyin Fuzheng Jiedu Prescription
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04264962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264962.